ArticleFrontiers in pediatrics2025
Comparison of the efficacy of aerosolized inhalation of different doses of recombinant human interferon alpha1b combined with budesonide in the treatment of asthmatic bronchitis in children.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthmatic Bronchitis (AB) is the most common type of bronchitis in children, severely affecting their quality of life and growth. This study aimed to investigate the efficacy and safety of aerosol inhalation of different doses of Recombinant Human Interferon alpha1b (IFNα1b) combined with budesonide in treating childhood AB. Methods: This was a retrospective cohort study. A total of 150 children with AB treated in our hospital from December 2022 to January 2025 were retrospectively screened. They were divided into three groups based on treatment protocols: control group (budesonide alone), low-dose group (2.0 µg/kg IFNα1b+ budesonide), and high-dose group (3.0 µg/kg IFNα1b+ budesonide). The three groups were matched 1:1:1 by gender, age, disease duration, and allergy history. The primary outcomes were the remission time of cough, wheezing, and pulmonary rales. The secondary outcomes included improvements in pulmonary function indices, changes in immunoglobulin levels, and adverse events. Results: After treatment, the remission times of cough, wheezing, and pulmonary rales in the high-dose group were significantly shorter than those in the low-dose and control groups, and the low-dose group was significantly shorter than the control group (all Conclusion: High-dose (3.0 µg/kg) IFNα1b combined with budesonide has certain advantages in improving cough, wheezing, pulmonary rales, pulmonary function, and immune status in children with AB, providing new clinical references for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.